ARTICLE | Clinical News
SYI-2074: Phase II discontinued
February 2, 2009 8:00 AM UTC
Synvista plans to discontinue an Israeli Phase II trial of topical SYI-2074 to conserve resources. The company has exclusive rights to SYI-2074 from Oxis. Novel Therapeutic developed the topical cream...